BioNexus Gene Lab Corp. (BGLC)
BioNexus Gene Lab Statistics
Share Statistics
BioNexus Gene Lab has 17.97M shares outstanding. The number of shares has increased by 0.98% in one year.
| Shares Outstanding | 17.97M |
| Shares Change (YoY) | 0.98% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 11.03M |
| Failed to Deliver (FTD) Shares | 2.22K |
| FTD / Avg. Volume | 0.06% |
Short Selling Information
The latest short interest is 140.38K, so 0.78% of the outstanding shares have been sold short.
| Short Interest | 140.38K |
| Short % of Shares Out | 0.78% |
| Short % of Float | 1.2% |
| Short Ratio (days to cover) | 2.21 |
Valuation Ratios
The PE ratio is -3.2 and the forward PE ratio is null. BioNexus Gene Lab's PEG ratio is -0.01.
| PE Ratio | -3.2 |
| Forward PE | n/a |
| PS Ratio | 0.86 |
| Forward PS | null |
| PB Ratio | 0.87 |
| P/FCF Ratio | -5.8 |
| PEG Ratio | -0.01 |
Enterprise Valuation
BioNexus Gene Lab Corp. has an Enterprise Value (EV) of 2.62M.
| EV / Earnings | -1 |
| EV / Sales | 0.27 |
| EV / EBITDA | -1.05 |
| EV / EBIT | -1.01 |
| EV / FCF | -1.8 |
Financial Position
The company has a current ratio of 4.93, with a Debt / Equity ratio of 0.01.
| Current Ratio | 4.93 |
| Quick Ratio | 4.24 |
| Debt / Equity | 0.01 |
| Total Debt / Capitalization | 1.36 |
| Cash Flow / Debt | -9.76 |
| Interest Coverage | -186.2 |
Financial Efficiency
Return on equity (ROE) is -0.27% and return on capital (ROIC) is -26.71%.
| Return on Equity (ROE) | -0.27% |
| Return on Assets (ROA) | -0.23% |
| Return on Capital (ROIC) | -26.71% |
| Revenue Per Employee | $325,693.53 |
| Profits Per Employee | $-87,634.77 |
| Employee Count | 30 |
| Asset Turnover | 0.86 |
| Inventory Turnover | 7.42 |
Taxes
| Income Tax | 21.53K |
| Effective Tax Rate | -0.01 |
Stock Price Statistics
The stock price has increased by -57.51% in the last 52 weeks. The beta is 1.69, so BioNexus Gene Lab's price volatility has been higher than the market average.
| Beta | 1.69 |
| 52-Week Price Change | -57.51% |
| 50-Day Moving Average | 0.35 |
| 200-Day Moving Average | 0.39 |
| Relative Strength Index (RSI) | 40.71 |
| Average Volume (20 Days) | 3.94M |
Income Statement
In the last 12 months, BioNexus Gene Lab had revenue of 9.77M and earned -2.63M in profits. Earnings per share was -0.17.
| Revenue | 9.77M |
| Gross Profit | 1.33M |
| Operating Income | -2.59M |
| Net Income | -2.63M |
| EBITDA | -2.49M |
| EBIT | -2.59M |
| Earnings Per Share (EPS) | -0.17 |
Balance Sheet
The company has 5.93M in cash and 133.4K in debt, giving a net cash position of 5.8M.
| Cash & Cash Equivalents | 5.93M |
| Total Debt | 133.4K |
| Net Cash | 5.8M |
| Retained Earnings | -1.84M |
| Total Assets | 11M |
| Working Capital | 5.62M |
Cash Flow
In the last 12 months, operating cash flow was -1.3M and capital expenditures -149.4K, giving a free cash flow of -1.45M.
| Operating Cash Flow | -1.3M |
| Capital Expenditures | -149.4K |
| Free Cash Flow | -1.45M |
| FCF Per Share | -0.09 |
Margins
Gross margin is 13.61%, with operating and profit margins of -26.54% and -26.91%.
| Gross Margin | 13.61% |
| Operating Margin | -26.54% |
| Pretax Margin | -26.69% |
| Profit Margin | -26.91% |
| EBITDA Margin | -25.43% |
| EBIT Margin | -26.54% |
| FCF Margin | -14.85% |
Dividends & Yields
BGLC does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -56.67% |
| FCF Yield | -26.99% |
Analyst Forecast
Currently there are no analyst rating for BGLC.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Jul 20, 2023. It was a backward split with a ratio of 1:12.
| Last Split Date | Jul 20, 2023 |
| Split Type | backward |
| Split Ratio | 1:12 |
Scores
| Altman Z-Score | 2.72 |
| Piotroski F-Score | 0 |